Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCP-Tacro once daily versus Prograf twice daily in de novo adult kidney transplant recipients
2008-003241-89Phase 3Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Oct 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in kidney allograft rejection and acute rejection (AR) comparing LCP-Tacro once daily + mycophenolate mofetil with Prograf twice daily + mycophenolate mofetil (2 arms). Primary endpoint: Proportion of treatment failures within 12 months. Started Oct 2010; status: completed.
02
Drugs
Envarsus XRtacrolimusmycophenolate mofetil
03
Conditions
kidney allograft rejectionacute rejection (AR)
Beyond the preview
Go deeper on 2008-003241-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003241-89.